Janssen submits MAA to European Medicines Agency for daratumumab in multiple myeloma
Daratumumab is an investigational, human anti-CD38 monoclonal antibody, which is designed to treat patients with relapsed and refractory multiple myeloma. Multiple myeloma is an incurable blood cancer that
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.